Up to 10 Years of Follow-Up Uphold Survival Benefit With Adjuvant Dabrafenib/Trametinib in Stage III Melanoma
The COMBI-AD dataset is the longest follow-up to date of adjuvant treatment for patients with stage III melanoma.
Western Australia New South Wales Innovent Biologics Pierre Fabre Boehringer Ingelheim Bristol Myers Squibb
Source: onclive.com